SUDEEPPHRM

Current scenario - Q2 FY27 revenue reached INR196 crores (up 21% YoY, 24% QoQ); EBITDA stood at INR73 crores (up 32% YoY); - PAT stood at INR51 crores (up 11% YoY), impacted by a higher effective blended tax rate and lower other income; - Principal operating challenge was logistics, particularly elevated sea freight costs, leading to selling and distribution expenses approximately INR8 crores above normal quarterly average; - PFN delivered strong growth with revenue up 57% YoY to INR142 crores, driven by phosphate portfolio and new customer additions; - Specialty Ingredients revenue down 25% YoY due to a temporary pause in the Indian government's Fortified Rice program and softer NSS performance. Changes in trends - Gross margin improved to 64.7% (vs 62.5% YoY), and EBITDA margin increased to 37.2% (up over 300 bps); - Greenfield facility at Nandesari received FDA approval during the quarter, with commercial supplies expected in H2 FY27; - Supply chain costs remained elevated above normal levels; new greenfield plant capitalized and put to use, adding to P&L expenses. Management Guidance & Outlook - Specialty Ingredients expected to return to positive YoY growth in Q3 and Q4 driven by new non-fortified rice customer contracts and approvals; - Magnesium bisglycinate commercial supplies started, with expectations to become a top 3 revenue contributor within PFN over the next 2-3 years; - Battery Materials (Dahej project) on track to commence commercial operations in April 2027, with firm binding offtake contracts expected in Q4; - Target to bring down working capital cycle to 170-180 days (excluding Battery Materials inventory) in FY27.

- Sudeep Pharma Limited has submitted the audio recording link of the Earnings Call held on 29th October 2026. - The audio recording can be accessed on the company's website.

Q2 FY27 Consolidated Revenue ₹196.7Cr vs ₹162.7Cr (▲21% YoY) EBITDA ₹73.2Cr vs ₹55.5Cr (▲32% YoY) PAT ₹51.8Cr vs ₹46.7Cr (▲11% YoY) EBITDA Margin 37.2% vs 34.1% (▲310bps)

Q2 FY27 Consolidated Revenue ₹196.70 Cr vs ₹162.67 Cr (▲21% YoY) EBITDA ₹73.24 Cr vs ₹55.46 Cr (▲32% YoY) PAT ₹51.81 Cr vs ₹46.78 Cr (▲11% YoY) EBITDA Margin 37.2% vs 34.1% (▲313bps)

- Sudeep Pharma Limited received FDA approval for its new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, authorizing the commencement of operations. - The facility features an annual installed capacity of 51,200 MT, supporting Pharma, Food & Nutrition, and Specialty Ingredients. - Commercial supplies are expected to begin in H2 FY27 following customer qualification processes. - Approximately 60% of capacity is allocated to existing portfolios, while the remainder caters to newer product categories like phosphates, glycinates, gluconates, citrates, and high-value bisglycinates.

Concall Schedule Concall Date: 29th October 2026 Concall Time: 12:00 noon.

- Mr. Sendhil Pani ceased to be Senior Management Personnel (Managing Director of Sudeep Pharma USA Inc.) w.e.f. October 2, 2026. - Cessation is due to the completion of contractual arrangements.

- Trading window for dealing in securities will be closed for Designated Persons from October 1, 2026. - Closure will remain until 48 hours after declaration of un-audited financial results for Q2/H1 ending September 30, 2026. - Board meeting date will be communicated in due course.

- Concall Schedule - Concall Date: 28th September 2026 - Concall Time: 10:00 am onwards - Organised by: Nuvama Emerging India CEO Forum 2026

- Sudeep Pharma Limited announced the cancellation of the Analyst / Investor Plant Visit. - The visit was scheduled for 23rd and 24th September 2026. - The cancellation is due to "some exigencies."

- Plant Visit Schedule for Analyst / Institutional Investor meetings - Date: 23rd & 24th September 2026 - Time: 11:00 am onwards - Place: Gujarat - Discussions will be based on publicly available information.